12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation

Citer cette référence
HOUSSEL-DEBRY, Pauline, COILLY, Audrey, FOUGEROU-LEURENT, Claire, JEZEQUEL, Caroline, DUVOUX, Christophe, DE LEDINGHEN, Victor, RADENNE, Sylvie, KAMAR, Nassim, LEROY, Vincent, DI MARTINO, Vincent D., D'ALTEROCHE, Louis, CANVA, Valérie, CONTI, Filomena, DUMORTIER, Jerome, MONTIALOUX, Hélène, LEBRAY, Pascal, BOTTA-FRIDLUND, Danielle, TRAN, Albert, MORENO, Christophe, SILVAIN, Christine, BESCH, Camille, PERRE, Philippe, FRANCOZ, Claire, ABERGEL, Armando, HABERSETZER, Francois, DEBETTE-GRATIEN, Maryline, CAGNOT, Carole, DIALLO, Alpha, CHEVALIEZ, Stéphane, ROSSIGNOL, Emilie, VEISLINGER, Aurélie, DUCLOS-VALLEE, Jean-Charles C. et PAGEAUX, Georges-Philippe P., 2018. 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. Hepatology [en ligne]. 2018. Vol. 68, n° 4pp. 1277-1287. [Consultésans date]. DOI 10.1002/hep.29918. Consulté de : https://www.ncbi.nlm.nih.gov/pubmed/296333891. .